These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 6298849

  • 1. Naloxone, tardive dyskinesia, and endogenous beta-endorphin.
    Reker D, Anderson B, Yackulic C, Cooper TB, Banay-Schwartz M, Leon C, Volavka J.
    Psychiatry Res; 1982 Dec; 7(3):321-4. PubMed ID: 6298849
    [Abstract] [Full Text] [Related]

  • 2. High-dose destyrosine-gamma-endorphin in tardive dyskinesia.
    Korsgaard S, Casey DE, Gerlach J.
    Psychopharmacology (Berl); 1982 Dec; 78(3):285-6. PubMed ID: 6130557
    [Abstract] [Full Text] [Related]

  • 3. beta-Endorphin and naloxone in psychiatric patients: clinical and biological effects.
    Lehmann H, Nair NP, Kline NS.
    Am J Psychiatry; 1979 Jun; 136(6):762-6. PubMed ID: 220889
    [Abstract] [Full Text] [Related]

  • 4. Naloxone treatment for five days ineffective in schizophrenia. Neuroendocrine actions of the opiate antagonist.
    Naber D, Münch U, Wissmann J, Grosse R, Ritt R, Welter D.
    Acta Psychiatr Scand; 1983 Apr; 67(4):265-71. PubMed ID: 6305111
    [No Abstract] [Full Text] [Related]

  • 5. Effect of des-tyrosine-gamma-endorphin in tardive dyskinesia.
    Casey DE, Korsgaard S, Gerlach J, Jørgensen A, Simmelsgaard H.
    Arch Gen Psychiatry; 1981 Feb; 38(2):158-60. PubMed ID: 7011248
    [Abstract] [Full Text] [Related]

  • 6. A double blind trial of naloxone in the treatment of acute stroke.
    Fallis RJ, Fisher M, Lobo RA.
    Stroke; 1984 Feb; 15(4):627-9. PubMed ID: 6087500
    [Abstract] [Full Text] [Related]

  • 7. Determination of beta-endorphin in alcoholic patients in the acute stage of intoxication: relation with naloxone therapy.
    Barret L, Bourhis F, Buffet H, Danel V, Debru JL.
    Drug Alcohol Depend; 1987 Jan; 19(1):71-8. PubMed ID: 2949952
    [Abstract] [Full Text] [Related]

  • 8. Response of plasma beta-endorphin immunoreactivity to d-amphetamine and placebo in schizophrenic patients.
    Schulz SC, van Kammen DP, Pickar D, Cohen MR, Naber D.
    Psychiatry Res; 1982 Oct; 7(2):171-8. PubMed ID: 6292981
    [Abstract] [Full Text] [Related]

  • 9. Behavioral effects of opioid receptor antagonists in psychopathologic states.
    Janowsky DS, Judd LL, Huey LY, Risch SC, Segal DS.
    Psychiatr Clin North Am; 1983 Sep; 6(3):403-14. PubMed ID: 6316300
    [No Abstract] [Full Text] [Related]

  • 10. Idiopathic narcolepsy: effect of naloxone studied in one of three patients with unelevated beta-endorphin-like immunoreactivity plasma levels.
    Pasi A, Wettstein A, Foletta D, Gramsch C.
    J Clin Psychopharmacol; 1982 Jun; 2(3):216-7. PubMed ID: 6284804
    [No Abstract] [Full Text] [Related]

  • 11. Prolactin response in tardive dyskinesia.
    Wolf ME, Bowie L, Keener S, Mosnaim AD.
    Biol Psychiatry; 1982 Apr; 17(4):485-90. PubMed ID: 7082714
    [No Abstract] [Full Text] [Related]

  • 12. Opioid plasma levels in primary affective disorders. Effect of desimipramine therapy.
    Genazzani AR, Petraglia F, Facchinetti F, Monittola C, Scarone S, Brambilla F.
    Neuropsychobiology; 1984 Apr; 12(2-3):78-85. PubMed ID: 6098855
    [Abstract] [Full Text] [Related]

  • 13. Naloxone and naltrexone in mental illness and tardive dyskinesia.
    Volavka J, Anderson B, Koz G.
    Ann N Y Acad Sci; 1982 Apr; 398():97-102. PubMed ID: 6760771
    [No Abstract] [Full Text] [Related]

  • 14. Naloxone effects on beta-endorphin, cortisol, prolactin, growth hormone, HVA and MHPG in plasma of normal volunteers.
    Naber D, Pickar D, Davis GC, Cohen RM, Jimerson DC, Elchisak MA, Defraites EG, Kalin NH, Risch SC, Buchsbaum MS.
    Psychopharmacology (Berl); 1981 Apr; 74(2):125-8. PubMed ID: 6267643
    [Abstract] [Full Text] [Related]

  • 15. beta-Endorphin immunoreactivity in the plasma of psychiatric patients receiving electroconvulsive treatment.
    Inturrisi CE, Alexopoulos G, Lipman R, Foley K, Rossier J.
    Ann N Y Acad Sci; 1982 Apr; 398():413-23. PubMed ID: 6297361
    [No Abstract] [Full Text] [Related]

  • 16. Studies of beta-endorphin in psychiatric patients.
    Berger PA, Barchas JD.
    Ann N Y Acad Sci; 1982 Apr; 398():448-59. PubMed ID: 6297364
    [No Abstract] [Full Text] [Related]

  • 17. Enkephalin, morphine, and naloxone in tardive dyskinesia.
    Bjørndal N, Casey DE, Gerlach J.
    Psychopharmacology (Berl); 1980 Apr; 69(2):133-6. PubMed ID: 6779305
    [Abstract] [Full Text] [Related]

  • 18. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM, Yu SC, Lin CC.
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [Abstract] [Full Text] [Related]

  • 19. High-dose naloxone in tardive dyskinesia.
    Lindenmayer JP, Gardner E, Goldberg E, Opler LA, Kay SR, van Praag HM, Weiner M, Zukin S.
    Psychiatry Res; 1988 Oct; 26(1):19-28. PubMed ID: 3070611
    [Abstract] [Full Text] [Related]

  • 20. Calcium metabolism and abnormal involuntary movements (tardive dyskinesia) in psychosis.
    Youssef HA, Waddington JL.
    Acta Psychiatr Scand; 1988 Oct; 78(4):523-5. PubMed ID: 3227974
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.